Enterprise Value

8.255B

Cash

2.863B

Avg Qtr Burn

N/A

Short % of Float

3.24%

Insider Ownership

1.76%

Institutional Own.

98.93%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Remunity™ (treprostinil) Details
Pulmonary Hypertension (PH) WHO Group 1 (PAH)

Approved

Quarterly sales

Tyvaso (inhaled treprostinil) Details
Pulmonary Hypertension (PH) WHO Group 3

Approved

Quarterly sales

Tyvaso DPI™ (inhaled treprostinil) Details
Pulmonary Hypertension (PH) WHO Group 1 / (PAH)Pulmonary Hypertension (PH) WHO Group 3

Approved

Quarterly sales

Tyvaso (inhaled treprostinil) Details
Pulmonary fibrosis, Idiopathic pulmonary fibrosis

Phase 3

Data readout

Phase 3

Data readout

Tyvaso (inhaled treprostinil) Details
Pulmonary hypertension, Chronic obstructive pulmonary disease

Phase 3

Update

Trevyent® (treprostinil sodium) Details
Pulmonary Hypertension (PH) WHO Group 1 (PAH)

Failed

Discontinued